Skip to main content

Table 6 Rocket-AF study: primary safety outcomes

From: Battle of oral anticoagulants in the field of atrial fibrillation scrutinized from a clinical practice (the real world) perspective

Outcomes

Rivaroxaban

Warfarin

P

NNT/NNH

Major and non-major clinically relevant

14.91

14.52

0.442

333

≥2 g/dL Hb drop

3.60

3.45

0.576

667

Transfusion (>2 U)

2.77

2.26

0.019

196

Critical organ bleeding

0.82

1.18

0.007

278

Bleeding causing death

0.24

0.48

0.003

417

Hemorrhagic stroke

0.26

0.44

0.024

556

Intracranial hemorrhage

0.49

0.74

0.019

400

  1. NNH, number needed to harm; NNT, number needed to treat. Data from Mahaffey KW. AHA Scientific Sessions 2010.